CAR-T Cell Therapy Treatment in China

China's NMPA has approved seven CAR-T therapies — more than the United States or Europe — including satri-cel, the world's first CAR-T approved for a solid tumor. Approved products cover lymphoma, leukemia and multiple myeloma, with active trial access for other targets.

Approved CD19 or BCMA CAR-T: $89,000–$170,000 · drug plus the full treatment course; quoted per case
Home › Hospitals › CAR-T Cell Therapy

Quick answer

CAR-T cell therapy in China costs roughly $89,000–$170,000 for an approved CD19 or BCMA product including the full treatment course, or about $30,000–$80,000 for clinical-trial participation. China's NMPA has approved seven CAR-T therapies — more than the United States or Europe — including satri-cel, the world's first CAR-T approved for a solid tumor. Leading centres include the Cancer Hospital of CAMS and Peking University People's Hospital in Beijing, Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center in Guangzhou, and West China Lecheng Hospital in the Hainan Lecheng zone. Treatment runs over four to six weeks in China: records review and target-antigen testing, apheresis, a two-to-four-week manufacturing window, lymphodepleting chemotherapy, infusion, and ten to fourteen days of inpatient monitoring.

Who this is for

Typically a good fit if

  • Your cancer has come back or stopped responding after at least two lines of treatment
  • You have a B-cell lymphoma or B-cell acute lymphoblastic leukaemia — the approved CD19 products cover these
  • You have multiple myeloma that has relapsed after several lines of therapy, including a proteasome inhibitor and an IMiD — the approved BCMA products cover this
  • You have Claudin18.2-positive gastric or gastro-oesophageal junction adenocarcinoma after at least two prior lines — the indication satri-cel is approved for
  • You are well enough for intensive treatment (ECOG 0–1), with adequate heart, liver and kidney function, no active infection, and a tissue sample available for target-antigen testing

May not be suitable if

  • A solid tumour other than Claudin18.2-positive gastric or GEJ cancer — approved products cover blood cancers, and other solid-tumour CAR-T remains experimental
  • An active bacterial, viral or fungal infection — this has to be stabilised before CAR-T can be considered
  • Cancer involving the central nervous system (brain or spinal cord) — generally contraindicated because of the risk
  • Poor performance status (ECOG 3 or above) or significant cardiac, hepatic, renal or pulmonary impairment
  • Pregnancy, or current HIV infection

Diagnosis

Eligibility depends on the cancer type, how many prior lines of treatment have failed, organ function and the target antigen on the tumor. CD19, BCMA and Claudin18.2 status are confirmed by pathology review before anything else.

Treatment Options

CAR-T involves leukapheresis, a two-to-four-week manufacturing window, lymphodepleting chemotherapy and infusion, followed by roughly ten to fourteen days of inpatient monitoring. China offers both approved products and clinical-trial access to experimental targets.

What the Treatment Involves

  1. Records review and eligibility3–7 days
    Send your diagnosis, pathology report, imaging and treatment history. Target-antigen testing (CD19, BCMA or Claudin18.2) has to be confirmed before anything else, and you receive a preliminary cost quote.
  2. Visa and travel7–14 days
    The hospital issues an official invitation letter for the M visa, which is normally processed within 4–10 business days.
  3. Apheresis (T-cell collection)Around weeks 3–4
    Your T cells are collected by leukapheresis, usually over one or two sessions, and shipped to the manufacturing site.
  4. Manufacturing window2–4 weeks
    The cells are engineered and expanded under GMP conditions. Bridging chemotherapy may be needed so the disease stays controlled while you wait.
  5. Lymphodepletion and infusion5 days, then 1 day
    A short course of fludarabine and cyclophosphamide prepares your body, then the engineered cells are infused and monitoring begins immediately.
  6. Inpatient monitoring10–14 days
    Close observation for cytokine release syndrome and neurological toxicity, with daily cytokine panels and tocilizumab or corticosteroids if needed. Major centres have 24/7 ICU-level backup.
  7. Discharge and follow-upMonths 1, 3, 6 and 12
    A PET-CT assesses response before discharge. Later scans and blood tests can be done in your home country with the results shared with the treating team.

Typical Costs in China

Approved CD19 or BCMA CAR-T $89,000–$170,000 drug plus the full treatment course; quoted per case
Satri-cel (Claudin18.2, gastric / GEJ) $89,000–$170,000 world's first approved solid-tumor CAR-T
Clinical trial participation ≈$30,000–$80,000 varies by trial; some costs covered
Travel, accommodation and monitoring ≈$3,500–$10,500 excluding the drug, for a 4–6 week stay

Prices are reference ranges; final quotes come from the hospital after case review.

Top Hospitals for CAR-T Cell Therapy

Cancer Hospital, CAMS
中国医学科学院肿瘤医院
🏆 #1 Oncology in China
📍 Beijing, Chaoyang
View Details →
Fudan University Shanghai Cancer Center
复旦大学附属肿瘤医院
🏆 Top 3 Oncology in China
📍 Shanghai, Xuhui
View Details →
Sun Yat-sen University Cancer Center
中山大学肿瘤防治中心
🏆 Top 3 Cancer Hospital in China
📍 Guangzhou, Yuexiu
View Details →
Peking University People's Hospital
北京大学人民医院
🏆 Top General Hospital
📍 Beijing, Xicheng
View Details →
Foshan Fosun Chancheng Hospital
佛山复星禅诚医院
🏆 Grade III Class A General Hospital, JCI Accredited, #1 Non-Public Hospital in China (Ailibi)
📍 Foshan, Chancheng
View Details →
West China Lecheng Hospital
四川大学华西乐城医院
🏆 Grade 3A; West China Hospital system's Lecheng campus for new-technology translation
📍 Qionghai, Boao
View Details →

Frequently Asked Questions

Which hospital offers CAR-T therapy in China?

Leading centres include the Cancer Hospital of CAMS and Peking University People's Hospital (Beijing), Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center (Guangzhou), and West China Lecheng Hospital in the Hainan Lecheng zone. Foshan Fosun Chancheng Hospital lists CAR-T among its oncology services. A case review confirms which of these can take your case.

How much does CAR-T therapy cost in China?

Reference ranges: approved CD19 or BCMA CAR-T runs roughly $89,000–$170,000 for the drug plus the full course, and clinical trial participation typically $30,000–$80,000. Budget about $3,500–$10,500 for travel, accommodation and monitoring over the 4–6 week stay. Confirm whether a quote includes tocilizumab, ICU standby and the full monitoring period, which are sometimes billed separately.

Is CAR-T a cure?

No. CAR-T has produced durable remissions in some blood cancers, but it is not a cure and it is not suitable for everyone. Response figures are reported at group level, and the treatment carries real risks including cytokine release syndrome and neurological toxicity.

Am I eligible for CAR-T therapy in China?

Eligibility depends on your cancer type, how many prior treatments have failed, organ function, and the target antigen on your tumour. In general, patients must have progressed after standard therapy, have adequate heart, liver and kidney function, no active infection, and no cancer spread to the central nervous system. A case review with your records and a tissue sample confirms whether you qualify.

What is the difference between approved CAR-T and a clinical trial?

Approved CAR-T products have cleared NMPA review for a defined indication, so the hospital can offer them as standard care. A clinical trial gives access to a product that is not yet approved — it may be more effective for your case, but outcomes are more uncertain and the screening criteria are stricter. Both routes exist in China and they are not interchangeable.

How long do I need to stay in China for CAR-T?

Plan for roughly four to six weeks in China. The sequence covers case review and target testing, apheresis, a manufacturing window of about two to four weeks, lymphodepleting chemotherapy, the infusion itself, and inpatient monitoring for about ten to fourteen days. Later follow-up scans can be done at home.

How this directory is checked

57 Grade 3A hospitals across 13 cities. 20 score 0.9 or above on our verification scale, and 5 were cross-checked against three or more independent sources. Every listing was last verified between 2026-04-06 and 2026-10-13.

What we check, and what we refuse to claim →

🛡️
100% Independent Guidance

We are not affiliated with any hospital. We don't take commissions. Our only goal is finding the right care for you.

Considering treatment for CAR-T Cell Therapy?

Tell us your diagnosis, scans and timing. We'll match you with the right Grade 3A hospital, compare likely costs, and outline the next practical step — free, no commitment.

Start Free Case Review →
All conditions: Coronary Artery Disease (CABG) Heart Valve Disease Lung Cancer Breast Cancer Liver Cancer Stomach (Gastric) Cancer Colorectal Cancer Brain Tumor Knee Replacement Hip Replacement Spine Surgery & Disc Herniation Parkinson's Disease & DBS Epilepsy IVF & Fertility Treatment LASIK & Vision Correction Cataract Surgery Dental Implants CAR-T Cell Therapy Advanced Heart Failure Cervical Cancer Stroke Rehabilitation
🏠Home 💰Pricing 📋Start
📧Email 💬WhatsApp 📨Telegram
📧 Email us 💬 Chat on WhatsApp 📨 Chat on Telegram 💬 WeChat: chinahospitalguide
🏥

Before You Go...

Finding the right hospital in China can be overwhelming. Let us help — free, no commitment.

⏳ Most cases get a hospital match within 24 hours

Start Free Case Review
No thanks, I'll keep searching